CanCertainty Coalition Applauds The Ontario PC Party’s Commitment To Equality For Cancer Patients News CanCertainty Coalition Applauds The Ontario PC Party’s Commitment To Equality For Cancer Patients
Obinutuzumab Reduces Risk of Disease Progression in Follicular Lymphoma News Obinutuzumab Reduces Risk of Disease Progression in Follicular Lymphoma
CANCER PATIENTS CELEBRATE NEW PROGRAM FOR TAKE-HOME CANCER MEDICATIONS IN NOVA SCOTIA News CANCER PATIENTS CELEBRATE NEW PROGRAM FOR TAKE-HOME CANCER MEDICATIONS IN NOVA SCOTIA
Hodgkin Lymphoma Patient Survey: Experience with Nivolumab (Opdivo) News Hodgkin Lymphoma Patient Survey: Experience with Nivolumab (Opdivo)
Hodgkin Lymphoma Patient Survey: Experience with Brentuximab-vedotin (Adcetris) News Hodgkin Lymphoma Patient Survey: Experience with Brentuximab-vedotin (Adcetris)
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression News Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression
Lymphoma Canada Awareness Day at Queen’s Park EventsNews Lymphoma Canada Awareness Day at Queen’s Park
New Targeted Therapy Safe and Effective in Refractory Non-Hodgkin’s Lymphoma Patients News New Targeted Therapy Safe and Effective in Refractory Non-Hodgkin’s Lymphoma Patients